Clinical Trials

First Line Hepato Cellular Carcinoma (HCC)

Location:

Trial status:

Inactive

Why is this study being done?

The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.

Who is eligible to participate?

Inclusion Criteria:

- Histologic or cytologic confirmed diagnosis of HCC.

- Advanced HCC: disease not eligible for surgical and/or locoregional therapies OR progressive disease after surgical and/or locoregional therapies

- Child-Pugh Class A

- ECOG performance status 0-1

- Adequate hematologic, hepatic, and renal function

Exclusion Criteria:

- Prior use of any systemic anti-cancer chemotherapy, immunotherapy or molecular targeted agents for HCC

- History of active cardiac disease

- Thrombotic or embolic events within the past 6 months (except HCC tumor thrombus)

- Any other hemorrhage/bleeding event >= CTCAE Grade 3 within 8 weeks except for esophageal or gastric varices

- Inability to swallow tablets or untreated malabsorption syndrome

Last updated: 08/21/2012

NCT ID:

NCT00858871